Vertex Pharmaceuticals (NASDAQ: VRTX)started the year on a high note with the approvalof its new cystic fibrosis drug, Symdeko. It posted solid first-quarter results, although the company announced it had to adjust its plans slightly for the next-generation triple combination cystic fibrosis drugs after the Food and Drug Administration (FDA) put up a roadblock.
[PREMIUM] Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться